Cadrenal launches strategic review for late-stage cardiology pipeline

Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal trial for its lead candidate, is now instead looking to offload its pipeline or potentially the entire company.